🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
547,09 USD
Máx. histórico
558,88
7 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,11%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+0,85%
Cierre anterior
542,50
Rango de hoy
531,53 – 548,76
Volumen hoy
1.271.214
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 35,21 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 5 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 06/03/2012 | 40,10 | 40,22 | 38,90 | 39,69 | -1,76% | 3,29% | 2.210.100 |
| 05/03/2012 | 40,50 | 40,81 | 40,15 | 40,40 | -0,81% | 1,63% | 2.665.800 |
| 02/03/2012 | 40,19 | 40,91 | 40,00 | 40,73 | +0,89% | 2,26% | 2.142.900 |
| 01/03/2012 | 38,93 | 40,79 | 38,31 | 40,37 | +3,73% | 6,37% | 4.023.800 |
| 29/02/2012 | 38,24 | 39,48 | 38,18 | 38,92 | +1,75% | 3,40% | 3.038.500 |
| 28/02/2012 | 38,70 | 38,74 | 38,15 | 38,25 | -1,14% | 1,52% | 1.812.900 |
| 27/02/2012 | 38,19 | 38,92 | 37,76 | 38,69 | +0,78% | 3,04% | 2.295.700 |
| 24/02/2012 | 38,90 | 39,00 | 38,00 | 38,39 | -0,65% | 2,57% | 1.836.800 |
| 23/02/2012 | 37,71 | 39,20 | 37,50 | 38,64 | +2,77% | 4,51% | 3.468.600 |
| 22/02/2012 | 37,68 | 37,96 | 37,22 | 37,60 | -0,45% | 1,96% | 1.946.500 |
| 21/02/2012 | 39,25 | 39,38 | 37,35 | 37,77 | -3,75% | 5,17% | 3.251.600 |
| 17/02/2012 | 40,70 | 40,70 | 39,00 | 39,24 | +4,67% | 4,18% | 8.695.200 |
| 16/02/2012 | 36,59 | 37,89 | 36,53 | 37,49 | +2,77% | 3,72% | 2.445.900 |
| 15/02/2012 | 36,30 | 36,70 | 36,04 | 36,48 | +0,97% | 1,82% | 1.434.400 |
| 14/02/2012 | 36,15 | 36,81 | 36,02 | 36,13 | -0,06% | 2,19% | 2.145.500 |
| 13/02/2012 | 36,47 | 36,55 | 36,02 | 36,15 | +0,06% | 1,45% | 1.374.800 |
| 10/02/2012 | 36,83 | 37,00 | 36,06 | 36,13 | -2,46% | 2,55% | 1.777.200 |
| 09/02/2012 | 37,13 | 37,23 | 35,98 | 37,04 | +0,71% | 3,37% | 3.253.200 |
| 08/02/2012 | 37,11 | 37,39 | 36,45 | 36,78 | -2,15% | 2,53% | 2.982.700 |
| 07/02/2012 | 38,28 | 38,28 | 36,98 | 37,59 | -1,70% | 3,40% | 4.309.900 |
| 06/02/2012 | 35,64 | 38,41 | 35,64 | 38,24 | +3,97% | 7,77% | 4.799.600 |
| 03/02/2012 | 37,54 | 38,10 | 35,43 | 36,78 | -4,17% | 7,11% | 8.256.600 |
| 02/02/2012 | 37,95 | 38,50 | 37,22 | 38,38 | +1,45% | 3,37% | 4.072.800 |
| 01/02/2012 | 37,45 | 38,00 | 36,30 | 37,83 | +2,38% | 4,54% | 4.631.600 |
| 31/01/2012 | 34,90 | 38,62 | 34,75 | 36,95 | +6,36% | 11,09% | 11.612.200 |
| 30/01/2012 | 35,25 | 35,49 | 34,10 | 34,74 | -3,45% | 3,94% | 3.110.900 |
| 27/01/2012 | 35,46 | 36,12 | 35,38 | 35,98 | +0,73% | 2,09% | 2.452.600 |
| 26/01/2012 | 35,42 | 35,97 | 35,30 | 35,72 | +0,73% | 1,89% | 1.862.800 |
| 25/01/2012 | 35,19 | 35,73 | 34,72 | 35,46 | +1,34% | 2,87% | 3.005.600 |
| 24/01/2012 | 35,80 | 35,91 | 34,91 | 34,99 | -2,43% | 2,79% | 3.308.900 |